Acumen Pharmaceuticals, Inc. (ABOS) |
|
4.21 -0.08 (-1.86%)
|
09-27 16:00 |
|
Open: |
4.29 |
Pre. Close: |
4.29 |
|
High:
|
4.34 |
Low:
|
4.19 |
|
Volume:
|
190,655 |
Market Cap:
|
244(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:17:26 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 6.59  One year: 7.7 |
| Support: |
Support1: 4.11 Support2: 3.41 |
| Resistance: |
Resistance1: 5.64 Resistance2: 6.59 |
| Pivot: |
5.06 |
| Moving Average: |
MA(5): 4.38 MA(20): 5.32
MA(100): 5.89  MA(250): 5.78 |
| MACD: |
MACD(12,26): -0.6 Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 7 %D(3): 5.3 |
| RSI: |
RSI(14): 19.6 |
| 52-week: |
High: 11.31 Low: 3.51 |
| Average Vol(K): |
3-Month: 1,195 (K) 10-Days: 322 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ABOS ] has closed above bottom band by 10.0%. Bollinger Bands are 1.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.42 - 4.45 |
4.45 - 4.47 |
|
Low:
|
4.15 - 4.19 |
4.19 - 4.22 |
|
Close:
|
4.23 - 4.29 |
4.29 - 4.34 |
|
Company Description |
|
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. |
Headline News |
Tue, 19 Sep 2023
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update - MarketBeat
Mon, 18 Sep 2023
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This ... - Nasdaq
Sun, 17 Sep 2023
Acumen Pharmaceuticals, Inc.'s (NASDAQ:ABOS) largest shareholders are private equity firms with 38% ownership, individual investors own 26% - Yahoo Finance
Wed, 06 Sep 2023
Acumen Pharmaceuticals to Participate in the H.C. - GlobeNewswire
Tue, 08 Aug 2023
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights - Yahoo Finance
Fri, 28 Jul 2023
Does Acumen Pharmaceuticals Inc (ABOS) Have What it Takes to be in Your Portfolio Friday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
58 (M) |
| Shares Float |
27 (M) |
|
% Held by Insiders
|
7.8 (%) |
|
% Held by Institutions
|
51.7 (%) |
|
Shares Short
|
1,750 (K) |
|
Shares Short P.Month
|
1,550 (K) |
Stock Financials |
|
EPS
|
-1.06 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
4.11 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-16.8 |
|
Return on Equity (ttm)
|
-24.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.56 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.91 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-42 (M) |
|
Levered Free Cash Flow
|
-28 (M) |
Stock Valuations |
|
PE Ratio
|
-3.98 |
|
PEG Ratio
|
-0.5 |
|
Price to Book value
|
1.02 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-5.77 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
